Esmolol Pediatric Dose — Cardiovascular Infusions
Esmolol is an ultra-short-acting, cardioselective beta-1 adrenergic blocker that works by competitively inhibiting catecholamine-mediated increases in heart rate and myocardial contractility. Its extremely short half-life (approximately 9 minutes) makes it well suited for precise, titratable control of heart rate and blood pressure in acute pediatric settings. It is primarily used in the management of supraventricular tachyarrhythmias, hypertensive emergencies, and perioperative hemodynamic instability in children.
Pediatric Dosing
- Loading dose: 300–500 mcg/kg administered intravenously over 15 minutes
- Maintenance infusion: 50–250 mcg/kg/min continuous intravenous infusion, titrated to clinical response
The loading dose is given slowly over 15 minutes to reduce the risk of hypotension, followed immediately by a continuous infusion titrated within the maintenance range. Dose adjustments should be made incrementally and guided by heart rate, blood pressure, and clinical response.
Worked example — 20 kg child: Loading dose: 20 × 300–500 mcg/kg = 6,000–10,000 mcg (6–10 mg) over 15 minutes. Maintenance infusion: 20 × 50–250 mcg/kg/min = 1,000–5,000 mcg/min (1–5 mg/min). Consult institutional protocol for maximum dose limits and preparation concentrations.
Indications and Clinical Context
Esmolol is indicated for the acute management of hemodynamically significant supraventricular tachycardias (SVT), including atrial flutter and atrial fibrillation with rapid ventricular response, in pediatric patients who require rapid, titratable rate control. It is also employed in hypertensive urgencies and emergencies, particularly in the perioperative setting. Its use aligns with advanced cardiovascular life support principles for rate-controlling agents when vagal maneuvers and adenosine have been insufficient or are not appropriate.
Because of its very short duration of action, esmolol is especially useful in critically ill or hemodynamically tenuous children where rapid offset is desirable if adverse effects occur. It is typically administered in a PICU or monitored emergency setting with continuous hemodynamic monitoring.
Administration and Monitoring
Esmolol must be administered intravenously (IV); it is not appropriate for intramuscular or endotracheal delivery. The loading dose should be infused over 15 minutes via a dedicated, reliable IV access — central venous access is preferred for prolonged infusions given the potential for peripheral vein irritation. Continuous infusion rates should be titrated based on heart rate and blood pressure response.
- Route: IV only (central access preferred for ongoing infusion)
- Monitoring: Continuous cardiac monitoring, pulse oximetry, and frequent blood pressure measurement are essential throughout administration
- Adverse effects: Hypotension is the most common adverse effect; bradycardia, bronchospasm (use with caution in reactive airways disease), and injection-site reactions may also occur
- Contraindications: Decompensated heart failure, significant bradycardia, second- or third-degree heart block, and known hypersensitivity
- Max dose: Consult institutional protocol for weight-based maximum dose and infusion concentration limits
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.